Vivalytic - universal diagnosis platform enables rapid COVID-19 tests

How can BHCS make molecular laboratory diagnostics more accessible and universally applicable?
Combating the coronavirus pandemic: The Vivalytic analysis device from Bosch Healthcare Solutions enables rapid molecular diagnostic tests.


As early as 2015, BHCS wanted to introduce their new medical analysis technology to a broader market. To make this a reality, we were consulted, and applied the full spectrum of the IXDS design and development skills to the project: User Research, Service Design, Business Design, UX/UI Design, Industrial Design and Creative Technology. The new product, its associated services and business models were developed from the initial idea to a market-ready item.



Working closely with the BHCS team and future users such as laboratories, hospitals, and practices, we developed a system consisting of a product (Vivalytic) and its components (cartridges). The business model and platform strategy for suppliers marked a huge innovation for both the market and BHCS. After an extremely short development period of less than two years, Vivalytic was launched.



The product received both the Red Dot Design Award and the iF Design Award in 2018.

Application in the coronavirus pandemic


Aiming to support the fight against the coronavirus pandemic, Bosch developed a rapid molecular diagnostic test for the Vivalytic analyzier in March 2020, offering results in less than two and a half hours.

It's one of the world’s first fully automated molecular diagnostic tests that can be used directly by all medical institutions, quotes Bosch.

We want the Bosch rapid COVID-19 test to play a part in containing the coronavirus pandemic as quickly as possible.

Dr. Volkmar Denner, chairman of the board of management of Robert Bosch GmbH


video features

Media response


Selected media feedback on the rapid corona tests:

ZEIT Online
Der Spiegel
Manager Magazin
Deutsche Welle